Horizon Pharma (NASDAQ:HZNP) was upgraded by stock analysts at ValuEngine from a “hold” rating to a “buy” rating in a report issued on Saturday.
Other analysts also recently issued reports about the stock. Piper Jaffray Companies reissued a “buy” rating and issued a $22.00 price target on shares of Horizon Pharma in a report on Thursday, March 1st. Cowen reissued a “buy” rating and issued a $24.00 price target on shares of Horizon Pharma in a report on Thursday, March 1st. UBS set a $20.00 price target on shares of Horizon Pharma and gave the company a “buy” rating in a report on Thursday, March 1st. Cantor Fitzgerald set a $17.00 price target on shares of Horizon Pharma and gave the company a “buy” rating in a report on Wednesday, February 28th. Finally, Mizuho reissued a “buy” rating and issued a $18.00 price target on shares of Horizon Pharma in a report on Monday, May 7th. Three investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Horizon Pharma has an average rating of “Buy” and an average price target of $19.20.
Shares of Horizon Pharma opened at $16.17 on Friday, MarketBeat Ratings reports. The company has a quick ratio of 1.50, a current ratio of 1.56 and a debt-to-equity ratio of 2.17. Horizon Pharma has a fifty-two week low of $9.90 and a fifty-two week high of $16.19. The firm has a market capitalization of $2.53 billion, a price-to-earnings ratio of 13.70, a P/E/G ratio of 0.91 and a beta of 1.29.
Horizon Pharma (NASDAQ:HZNP) last issued its quarterly earnings results on Wednesday, May 9th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.08). Horizon Pharma had a negative net margin of 45.06% and a positive return on equity of 16.97%. The company had revenue of $223.88 million during the quarter, compared to the consensus estimate of $232.05 million. During the same period last year, the company earned $0.21 earnings per share. Horizon Pharma’s revenue for the quarter was up 1.4% on a year-over-year basis. equities research analysts expect that Horizon Pharma will post 1.43 earnings per share for the current fiscal year.
Several large investors have recently added to or reduced their stakes in HZNP. Ladenburg Thalmann Financial Services Inc. lifted its holdings in shares of Horizon Pharma by 74.4% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 9,091 shares of the biopharmaceutical company’s stock worth $128,000 after acquiring an additional 3,877 shares during the period. D.A. Davidson & CO. bought a new position in shares of Horizon Pharma during the 1st quarter worth about $143,000. Zweig DiMenna Associates LLC bought a new position in shares of Horizon Pharma during the 1st quarter worth about $156,000. BlueCrest Capital Management Ltd bought a new position in shares of Horizon Pharma during the 4th quarter worth about $160,000. Finally, K2 Principal Fund L.P. lifted its holdings in shares of Horizon Pharma by 126.1% during the 4th quarter. K2 Principal Fund L.P. now owns 11,074 shares of the biopharmaceutical company’s stock worth $162,000 after acquiring an additional 53,574 shares during the period. 84.33% of the stock is owned by institutional investors.
Horizon Pharma Company Profile
Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.